Evaxion's AI technology identifies cancer vaccine targets as

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated... | June 3, 2023

Related Keywords

Illinois , United States , Russia , Chicago , Denmark , Copenhagen , Køavn , Ukraine , Neopepvac Clinicaltrials , Exchange Commission , Securities Exchange , Globenewswire Inc , Per Norl , Chief Executive Officer , Neo Antigen Vaccine , Advanced Solid Tumors , Securities Act , Securities Exchange Act , Annual Report , Evaxion Biotech , Evaxion Biotechas Stock Exchange , News , Information , Press Release , The , Linical , Trial , F , Personalized , Dancer , Vaccine , Pet , Its , Primary , Endpoints , Safety , End , Olerabilitypositive , Responses , Were , Eported , N , , Nut , 2 Evax Us29970r1059 ,